SCHEMBL2920879

SCHEMBL2920879

CCC(O)OC(=O)c1ccc(C(=O)O)cc1C(=O)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 10/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 4/20 0.41
HPGD P15428 4/20 0.41
HSD17B10 Q99714 4/20 0.41
GLA P06280 2/20 0.41
GAA P10253 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128862 0.85 ALDH1A1 (0.49) KDM4EKMT2AALDH1A1LMNAMAPT
SCHEMBL820141 0.83 KDM4E (0.55) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL29699657 0.83 KDM4E (0.55) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL873754 0.81 TSHR (0.50) KDM4EKMT2AALDH1A1LMNAMAPT
SCHEMBL4885782 0.79 ALDH1A1 (0.43) KDM4EKMT2AALDH1A1LMNAHSD17B10
SCHEMBL5834949 0.79 KDM4E (0.50) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL293611 0.78 KDM4E (0.55) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL293610 0.78 KDM4E (0.53) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL2160586 0.77 MAPT (0.56) KMT2AALDH1A1MAPTTSHRMAPK1
Pentane SCHEMBL819070 0.77 ALDH1A1 (0.49) KDM4EKMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION 2025-07-31 US claimed
EP-4479092-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS Purdue Research Foundation (US) 2024-12-25 EP claimed
WO-2023154171-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION (US) 2023-08-17 WO claimed
US-20180311278-A1 PHARMACEUTICAL PREPARATION FOR DELIVERY OF POROUS MATERIAL TO LARGE INTESTINE OR LOWER PART OF SMALL INTESTINE DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-11-01 US claimed
EP-3369424-A1 POROUS MATERIAL FORMULATION FOR DELIVERY TO LARGE INTESTINE OR LOWER SMALL INTESTINE DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-09-05 EP claimed
EP-2827900-B1 AMORPHOUS SOLID DISPERSION FOR USE IN THE TREATMENT OF BRAIN CANCER ARRAY BIOPHARMA INC (US) 2018-03-21 EP claimed
EP-2765990-B1 SOLID DISPERSION ARRAY BIOPHARMA INC (US) 2017-09-06 EP claimed
EP-1399190-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS BEND RES INC (US) 2010-09-08 EP claimed
EP-4663198-A1 COMPOSITION CONTAINING CYCLIC PEPTIDE COMPOUND AND SURFACTANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-12-17 EP disclosed
US-20250302912-A1 COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-02 US disclosed
EP-4609875-A2 COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-03 EP disclosed
EP-4603546-A1 SOLID DISPERSION CONTAINING SUBSTANCE TO BE DISPERSED, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHODS THEREFOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-20 EP disclosed
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION 2025-07-31 US disclosed
EP-4166133-B1 COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-23 EP disclosed
EP-4166133-A1 COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-04-19 EP disclosed
CN-112770750-A Solid dispersion of hydantoin derivative 中外制药株式会社 2021-05-07 CN disclosed
WO-2020027011-A1 SOLID DISPERSION OF HYDANTOIN DERIVATIVE 中外製薬株式会社 2020-02-06 WO disclosed
CN-110636845-A Amorphous form and solid dispersion of rumepilone p-toluenesulfonate 雷迪博士实验室有限公司 2019-12-31 CN disclosed
US-20180311278-A1 PHARMACEUTICAL PREPARATION FOR DELIVERY OF POROUS MATERIAL TO LARGE INTESTINE OR LOWER PART OF SMALL INTESTINE DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-11-01 US disclosed
EP-3369424-A1 POROUS MATERIAL FORMULATION FOR DELIVERY TO LARGE INTESTINE OR LOWER SMALL INTESTINE DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS SRI, SYNGR2, PSD KDM4E 835/4885KMT2A 1269/4885ALDH1A1 3898/4885
US-20250302912-A1 COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT PCTP, CETP, PLTP KDM4E 4257/4885KMT2A 4487/4885ALDH1A1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.